• Decrease
• Increase

The Prostate Cancer Clinical Trials Consortium (PCCTC) is a 13-member clinical research group sponsored by the Prostate Cancer Foundation and the Department of Defense Prostate Cancer Research Program (PCRP) that offers simplified solutions for multicenter clinical trials. Capitalizing on their scientific and clinical expertise and unique institutional resources, PCCTC members collaborate to design, implement and complete phase I and phase II trials in prostate cancer to rapidly bring scientific discoveries to patients.

Latest News

Promising Results from PCCTC-Led Trial of Galeterone (TOK-00 (04/03/12)

Study Showed No Dose Limiting Toxicities with Galeterone; Preliminary Efficacy Data Reported CAMBRIDGE, MA. and CHICAGO, IL., March 31, 2012 — Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with [...]

Stand Up to Cancer Announces Prostate Cancer Dream Team (04/02/12)

Prostate cancer, like other types of cancer, is not a homogeneous disease. For example, up to 50 percent of treatment resistant metastatic prostate cancer (CRPC) patients have a genetic aberration called a “gene fusion” that involves two genes including ETS genes. Another 50 percent of patients may have a “deletion” or loss of an entire [...]

Zytiga Provides Benefit Prior to Chemotherapy (03/09/12)

Phase 3 trial finds Zytiga also improves survival, has a favorable safety profile in men with metastatic castration-resistant prostate cancer (mCRPC) who have not had chemotherapy.

PCCTC Investigators Highlight Program’s Success (03/09/12)

Four leading scientists discuss how the PCCTC accelerates prostate cancer clinical research.